Research graph
References from Ticagrelor Monotherapy or Aspirin Plus Prasugrel After Percutaneous Coronary Intervention. Local targets link to admitted publications; unresolved targets remain external evidence.
ACC/AHA 2007 guidelines for the management of patients with unstable Angina/Non–ST-Elevation myocardial infarction
10.1016/j.jacc.2007.02.028 · 2007 · External reference
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
10.1093/eurheartj/ehx419 · 2018 · External reference
2023 ESC guidelines for the management of acute coronary syndromes
10.1093/eurheartj/ehad191 · 2023 · External reference
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
10.1016/s0140-6736(01)05701-4 · 2001 · External reference
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
10.1056/nejmoa0904327 · 2009 · External reference
Prasugrel versus clopidogrel in patients with acute coronary syndromes
10.1056/nejmoa0706482 · 2007 · External reference
Demystifying the contemporary role of 12-Month dual antiplatelet therapy after acute coronary syndrome
10.1161/circulationaha.124.069012 · 2024 · External reference
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial
10.1016/s0140-6736(24)00473-2 · 2024 · External reference
Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial
10.1161/circulationaha.123.066943 · 2024 · External reference
Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome
10.1001/jama.2020.7580 · 2020 · External reference
Ticagrelor with or without aspirin in high-risk patients after PCI
10.1056/nejmoa1908419 · 2019 · External reference
Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting
10.1016/j.jacc.2019.08.1038 · 2019 · External reference
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials
10.1016/s0140-6736(24)01616-7 · 2024 · External reference
The 2025 ACS guideline update endorses ticagrelor monotherapy ≥1 month after DAPT Post-PCI
10.1016/j.jacc.2025.04.046 · 2025 · External reference
Ticagrelor or prasugrel in patients with acute coronary syndromes
10.1056/nejmoa1908973 · 2019 · External reference
Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease
10.1001/jamacardio.2025.5057 · 2026 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Unresolved reference
2024 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
10.1136/bmj.39489.470347.ad · 2008 · External reference
Evaluating the quality of evidence from a network meta-analysis
10.1371/journal.pone.0099682 · 2014 · External reference
Graphical tools for network meta-analysis in STATA
10.1371/journal.pone.0076654 · 2013 · External reference
Ranking treatments in frequentist network meta-analysis works without resampling methods
10.1186/s12874-015-0060-8 · 2015 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes
10.1001/jamacardio.2019.3355 · 2019 · External reference
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
10.1093/eurheartj/ehaa670 · 2020 · External reference
Efficacy and safety of prasugrel, ticagrelor, or clopidogrel after percutaneous coronary intervention
10.1001/jamacardio.2026.1128 · 2026 · External reference
P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis
10.1093/eurheartj/ehag381 · 2026 · External reference
Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes
10.1001/jamacardio.2024.3216 · 2024 · External reference
Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus
10.1016/j.jcin.2020.07.032 · 2020 · External reference
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease
10.1161/circinterventions.110.960187 · 2011 · External reference
Diabetes and antiplatelet therapy in acute coronary syndrome
10.1161/circulationaha.109.913376 · 2011 · External reference
Randomized assessment of ticagrelor versus Prasugrel antiplatelet effects in patients with diabetes
10.2337/dc12-2510 · 2013 · External reference
Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease
10.1161/circulationaha.116.023402 · 2016 · External reference
Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with Non–ST-Elevation acute coronary syndrome undergoing percutaneous coronary intervention
10.1161/circinterventions.113.000293 · 2013 · External reference
Adenosine-mediated effects of ticagrelor
10.1016/j.jacc.2014.03.031 · 2014 · External reference
Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans
10.1016/j.jacc.2012.11.032 · 2013 · External reference
Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with Non–ST-Segment elevation acute coronary syndrome requiring coronary stenting
10.1016/j.jcin.2017.05.064 · 2017 · External reference
An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial
10.1161/circulationaha.123.066720 · 2024 · External reference
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
10.4244/eij-d-25-00331 · 2025 · External reference
